当前位置: X-MOL 学术FEBS J. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Immunomodulation via macrophages to fight solid tumor malignancies
The FEBS Journal ( IF 5.5 ) Pub Date : 2020-06-23 , DOI: 10.1111/febs.15437
Hiren Dandia 1 , Prakriti Tayalia 1
Affiliation  

The paper ‘A C‐Terminal Fragment of Adhesion Protein Fibulin‐7 Inhibits Growth of Murine Breast Tumor by Regulating Macrophage Reprogramming’ by Chakraborty et al. highlights that Fbln7‐C could be explored as a potential immunomodulatory agent against various solid cancers and have shown its abilities to regulate tumor microenvironment reprogramming of TAMs in a breast cancer model. Fbln7, which is a secreted glycoprotein, has been shown to be anti‐angiogenic and has an immunomodulatory role regulating various functional properties of monocytes, macrophages, and neutrophils, thereby influencing inflammation. In this study, the authors have shown that in a murine breast tumor model, intravenous administration of Fbln7‐C significantly reduces the size of tumors via macrophage reprogramming.

中文翻译:

通过巨噬细胞进行免疫调节以对抗实体瘤恶性肿瘤

Chakraborty等人的论文“通过调节巨噬细胞重编程来抑制粘附蛋白纤维蛋白7的AC末端片段抑制小鼠乳腺癌的生长” 。强调了Fbln7‐C可以作为一种针对各种实体癌的潜在免疫调节剂进行研究,并已显示出它具有调节乳腺癌模型中TAM的肿瘤微环境重编程的能力。Fbln7是一种分泌的糖蛋白,已被证明具有抗血管生成作用,并具有调节单核细胞,巨噬细胞和嗜中性粒细胞各种功能特性的免疫调节作用,从而影响炎症。在这项研究中,作者表明,在小鼠乳腺肿瘤模型中,通过巨噬细胞重编程,静脉内施用Fbln7-C可以显着减小肿瘤的大小。
更新日期:2020-06-23
down
wechat
bug